PH24669A - Novel 9-diazaguanines - Google Patents

Novel 9-diazaguanines

Info

Publication number
PH24669A
PH24669A PH35723A PH35723A PH24669A PH 24669 A PH24669 A PH 24669A PH 35723 A PH35723 A PH 35723A PH 35723 A PH35723 A PH 35723A PH 24669 A PH24669 A PH 24669A
Authority
PH
Philippines
Prior art keywords
novel
cells
diazaguanines
derivatives
deoxyguanosine
Prior art date
Application number
PH35723A
Other languages
English (en)
Inventor
Catherine Rose Kostland
Jagadish Chandra Sircar
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PH24669A publication Critical patent/PH24669A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Luminescent Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
PH35723A 1986-08-26 1987-08-24 Novel 9-diazaguanines PH24669A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90048686A 1986-08-26 1986-08-26
US5941987A 1987-06-18 1987-06-18

Publications (1)

Publication Number Publication Date
PH24669A true PH24669A (en) 1990-09-07

Family

ID=26738724

Family Applications (1)

Application Number Title Priority Date Filing Date
PH35723A PH24669A (en) 1986-08-26 1987-08-24 Novel 9-diazaguanines

Country Status (16)

Country Link
EP (1) EP0260491B1 (da)
JP (2) JP2595254B2 (da)
KR (2) KR940008421B1 (da)
AT (1) ATE67203T1 (da)
AU (1) AU619724B2 (da)
CA (2) CA1293727C (da)
DE (1) DE3772913D1 (da)
DK (1) DK169705B1 (da)
ES (1) ES2038635T3 (da)
FI (1) FI85856C (da)
GR (1) GR3002697T3 (da)
IE (1) IE60433B1 (da)
NO (1) NO166485C (da)
NZ (1) NZ221463A (da)
PH (1) PH24669A (da)
PT (1) PT85582B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1294960C (en) * 1986-10-24 1992-01-28 Thomas C. Malone 7-deazaguanines as immunomodulators
ATE157363T1 (de) * 1989-02-27 1997-09-15 Biocryst Pharm Inc 9-substituierte-8-unsubstituierte-9-deazaguanin
CA2072123C (en) * 1989-10-31 2001-06-12 John A. Secrist, Iii Inhibitors of purine nucleoside phosphorylase
US5726311A (en) * 1989-11-29 1998-03-10 Biocryst Pharmaceuticals, Inc. 7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo 3,2-d!pyrimidine and pharmaceutical uses and compositions containing the same
AU6855594A (en) * 1993-06-30 1995-01-24 Biocryst Pharmaceuticals, Inc. 9-deazahypoxanthines as pnp inhibitors
US5386031A (en) * 1993-12-15 1995-01-31 Warner-Lambert Company Process for the synthesis of 2-amino-3,5-dihydro-7-substituted-4H-pyrrolo[3,]pyrimidin-4-ones
WO1996011200A1 (en) * 1994-10-05 1996-04-18 Chiroscience Limited Purine and guanine compounds as inhibitors of pnp
FR2728181B1 (fr) * 1994-12-16 1997-01-31 Appryl Snc Composante catalytique pour la polymerisation des olefines, son procede de fabrication, et procede de polymerisation des olefines en presence de ladite composante catalytique
DE69531558T2 (de) * 1995-06-07 2004-03-18 Pfizer Inc. Heterocyclische kondensierte pyrimidin-derivate
US6395733B1 (en) 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
NZ523970A (en) * 2003-02-04 2005-02-25 Ind Res Ltd Process for preparing inhibitors of nucleoside phoshorylases and nucleosidases
KR20060120069A (ko) * 2003-10-03 2006-11-24 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피라졸로피리딘 및 그의 유사체
NZ540160A (en) * 2005-05-20 2008-03-28 Einstein Coll Med Inhibitors of nucleoside phosphorylases
GB201417165D0 (en) * 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease
GB201417163D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164556B (da) * 1986-03-06 1989-04-08 Takeda Chemical Industries Ltd
CA1294960C (en) * 1986-10-24 1992-01-28 Thomas C. Malone 7-deazaguanines as immunomodulators
DE3739366A1 (de) * 1987-04-10 1988-10-27 Boehringer Mannheim Gmbh Desaza-purin-nucleosid-derivate, verfahren zu deren herstellung sowie deren verwendung bei der nucleinsaeure-sequenzierung sowie als antivirale mittel

Also Published As

Publication number Publication date
FI873648A (fi) 1988-02-27
ES2038635T3 (es) 1993-08-01
EP0260491A1 (en) 1988-03-23
NO166485C (no) 1991-07-31
IE872070L (en) 1988-02-26
PT85582A (en) 1987-09-01
FI85856C (fi) 1992-06-10
KR940008848B1 (ko) 1994-09-28
FI873648A0 (fi) 1987-08-24
JP2650644B2 (ja) 1997-09-03
NO873584D0 (no) 1987-08-25
ATE67203T1 (de) 1991-09-15
IE60433B1 (en) 1994-07-13
KR880002873A (ko) 1988-05-12
EP0260491B1 (en) 1991-09-11
JP2595254B2 (ja) 1997-04-02
NO873584L (no) 1988-02-29
AU619724B2 (en) 1992-02-06
NO166485B (no) 1991-04-22
DK169705B1 (da) 1995-01-16
JPH08311040A (ja) 1996-11-26
GR3002697T3 (en) 1993-01-25
JPS6388185A (ja) 1988-04-19
FI85856B (fi) 1992-02-28
NZ221463A (en) 1990-07-26
DK440287D0 (da) 1987-08-24
KR940008421B1 (ko) 1994-09-14
AU7741687A (en) 1988-03-03
CA1320203C (en) 1993-07-13
DK440287A (da) 1988-02-27
CA1293727C (en) 1991-12-31
PT85582B (pt) 1990-05-31
DE3772913D1 (de) 1991-10-17

Similar Documents

Publication Publication Date Title
AU619724B2 (en) Novel 9 - deazaguanines
HUT52769A (en) Process for producing pyrimidine derivatives and pharmaceutical compositions containing them
HUT70505A (en) Pyrrolo[2,3-d]pyrimidine derivatives, pharmaceutical compositions containing them and process for preparing them
AU3399889A (en) Immunostimulating guanine derivatives, compositions and methods
MX9709859A (es) Inhibidores de adenosina cinasa modificados en c-4.
DK224286D0 (da) 2',3'-dideoxy-nucleosider
AU5514190A (en) Tumor necrosis factor binding protein II, it's purification and antibodies thereto
FI956168A (fi) Uudet kemialliset yhdisteet, joilla on PDE-IV:ää inhiboivaa aktiivisuutta
LV5273A3 (lv) Panemiens pirimidinnukleozidu iegusanai
PT85551A (en) Process for the preparation of antiviral pyrimidine derivatives and of pharmaceutical compositions containing the same
DK322189D0 (da) Imidazo(1,2-a)-(pyridaziner eller pyraziner) til behandling af sygdomme med relation til knogletab
ZA872998B (en) Furo(3,4-d)pyrimidine-2,4-dione derivatives and intermediates thereof
EP0553294A4 (en) Methods and compositions for the treatment of cell proliferation disorders
PT84478A (en) Pyrazolo ]3,4-d" pyrimidine derivatives their production and use
GB9214053D0 (en) Heterocyclic amides
GB8822546D0 (en) Antiviral combinations
AU2527688A (en) Artificial dna base pair analogues
NZ224958A (en) Process for preparation of purine derivatives and intermediate pyrimidines
MY103593A (en) Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation
GR852525B (da)
NZ231478A (en) 5-prop-1-ynyl-1-(5-0-trimethylacetyl-beta-d-arabinofuranosyl)-uracil
NZ219598A (en) Composition of tissue plasminogen activator and oxypurinol (ie 1h-pyrazolo(3,4-d)pyrimidine-4,6(5h,7h)-dione)
AU587562B2 (en) Adjustable supply of solid particles to one or more receiving stations
ES2062351T3 (es) Derivados de triazolo (4,5-c) piridina anticonvulsivos.